Greater than 50% of ER+PR+ tumors contain ER-PR-K5+ subpopulations [26] and K5+ cells are increased in ER+ breast tumors following treatment with neoadjuvant endocrine therapy [25]. The gene discussed is KRT5; the disease is breast neoplasm.